# Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

> **NCT02120157** · PHASE2 · COMPLETED · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 35 (actual)

## Conditions studied

- Myeloablative Conditioning
- HLA-mismatched Bone Marrow Transplantation
- Graft Survival
- Transplantation, Bone Marrow

## Interventions

- **DRUG:** Cyclophosphamide
- **RADIATION:** TBI
- **DRUG:** Busulfan
- **OTHER:** Unmanipulated Bone Marrow
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolate mofetil

## Key facts

- **NCT ID:** NCT02120157
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-02
- **Primary completion:** 2018-06-15
- **Final completion:** 2020-10-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2021-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02120157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02120157, "Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02120157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*